Revance Therapeu Stock Price, News & Analysis

Revance Therapeutics (RVNC) reported Q4 and full-year 2020 revenues of $11.1 million and $15.3 million, a significant increase from $0.1 million and $0.4 million in 2019. This growth is attributed to the launch of the RHA® Collection of dermal fillers and the HintMD platform.

Net losses were $78.3 million for Q4 and $282.1 million for the full year. Total operating expenses rose to $89.1 million in Q4, up from $46.3 million in 2019. The firm anticipates BLA approval for DaxibotulinumtoxinA in 2021, bolstering future growth prospects.

Revance Therapeutics, Inc. (Nasdaq: RVNC) announced positive topline data from its JUNIPER Phase 2 trial of DaxibotulinumtoxinA for Injection, aimed at treating moderate to severe upper limb spasticity. The study evaluated three doses (250, 375, 500 units) in 83 subjects due to COVID-19-related enrollment challenges. Results indicated a statistically significant muscle tone reduction with the 500-unit dose (p=0.0488) and a median duration of effect of at least 24 weeks across doses. The treatment was well tolerated, suggesting potential benefits in treatment frequency and patient quality of life.

Revance Therapeutics, Inc. (Nasdaq: RVNC) announced the appointments of Olivia C. Ware and Carey O’Connor Kolaja to its Board of Directors, effective March 1, 2021, and March 6, 2021, respectively. The company emphasizes that enhancing board expertise aligns with its growth strategy. This change follows the retirement of long-standing directors Phyllis Gardner and Robert Byrnes, adhering to a 12-year tenure policy aimed at board refreshment and diversity. Ware brings over 20 years of biotech experience, while Kolaja has extensive fintech and payments expertise.

Revance Therapeutics, Inc. (Nasdaq: RVNC) will release its fourth quarter and full year 2020 financial results on February 22, 2021, after market close. A conference call is scheduled for 1:30 p.m. PT / 4:30 p.m. ET to discuss these results and provide updates on the business and pipeline. Interested listeners can join via phone or through a live webcast available on the company’s website. Revance focuses on innovative aesthetic and therapeutic products, including its DaxibotulinumtoxinA for Injection, which is pending U.S. regulatory approval following a successful Phase 3 program.

Revance Therapeutics, Inc. (Nasdaq: RVNC) announced the presentation of three ePosters at the Maui Derm for Dermatologists 2021 meeting, showcasing findings from the Phase 2 study of DaxibotulinumtoxinA for Injection for treating upper facial lines. The data highlight progressive improvement in static glabellar lines with repeated treatments, along with in vitro results on the RHA® Collection fillers. Revance aims to establish DaxibotulinumtoxinA as a new standard in facial aesthetics, with U.S. regulatory approval for glabellar lines pending.

Revance Therapeutics, Inc. (Nasdaq: RVNC) announced the issuance of 75,400 inducement restricted stock awards (RSAs) to 15 new employees, with a vesting schedule of four years. This action aims to incentivize the new hires, aligning with NASDAQ Listing Rule 5635(c)(4). Revance focuses on innovative aesthetic and therapeutic products, notably its investigational neuromodulator DaxibotulinumtoxinA for Injection, which has completed Phase 3 trials for glabellar lines and seeks U.S. regulatory approval.

Revance Therapeutics, Inc. (Nasdaq: RVNC), a biotechnology company specializing in aesthetic and therapeutic innovations, will join the 39th Annual J.P. Morgan Healthcare Conference on January 14, 2021. CEO Mark Foley is set to present at 12:40 p.m. PT / 3:40 p.m. ET. The live audio webcast can be accessed on their Investor Relations page, with a replay available for 30 days post-presentation. Revance is advancing its DaxibotulinumtoxinA for Injection, currently seeking U.S. regulatory approval after completing a Phase 3 trial for glabellar lines.

Revance Therapeutics, Inc. (Nasdaq: RVNC) provided a corporate update detailing its product pipeline and financial metrics for 2020. The company reported preliminary RHA® Collection revenues between $12.5 million and $13.0 million, with Q4 revenues estimated at $9.5 million to $10.0 million. Revance anticipates over $200 million in HintMD processing volume by year-end 2020. The firm maintains a strong cash position, forecasting funding into 2023. FDA approval for DaxibotulinumtoxinA for Injection is anticipated in 2021, with positive clinical results for its aesthetics products reported.